4//SEC Filing
Fenton Mary Kay 4
Accession 0001209191-23-006978
CIK 0001827506other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 4:57 PM ET
Size
8.5 KB
Accession
0001209191-23-006978
Insider Transaction Report
Form 4
Fenton Mary Kay
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-02-01+150,000→ 150,000 totalExercise: $1.73Exp: 2033-02-01→ Common Stock (150,000 underlying) - Award
Stock Appreciation Right
2023-02-01+150,000→ 150,000 totalExercise: $1.73Exp: 2033-02-01→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024.
- [F2]Each Time Vested Stock Appreciation Right ("TV SAR") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date.
Documents
Issuer
Talaris Therapeutics, Inc.
CIK 0001827506
Entity typeother
Related Parties
1- filerCIK 0001378589
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 4:57 PM ET
- Size
- 8.5 KB